Breakthrough in vitro research

Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19. IMM-124E is used in Immuron’s over-the-counter Travelan and Protectyn products which were developed as immunotherapeutics to prevent travellers’ [...]

Immuron partners with Walter Reed Army Institute of Research to investigate countermeasures against diarrheal disease during deployment

Walter Reed Army Institute of Research's mission is to discover, design and develop solutions for military relevant infectious disease and brain health threats through innovative research protecting and optimizing warfighter lethality. Studies by the Military Infectious Disease Research Program's Infectious [...]

Go to Top